SCHEMBL5726272

SCHEMBL5726272

Nc1ccc(S(=O)(=O)n2cc(CC3CCNCC3)c3cccnc32)cc1

nearest known ligand 0.51

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 17/20 0.51
▸ HTR1A P08908 2/20 0.42
▸ CCNE1 P24864 2/20 0.41
▸ CDK2 P24941 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ HTR7 P34969 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5727247 0.90 HTR6 (0.58) HTR6CCNE1CDK2
SCHEMBL5726304 0.83 HTR6 (0.72) HTR6HTR1AHTR7
SCHEMBL1772540 0.82 HTR6 (0.64) HTR6CCNE1CDK2
SCHEMBL5725607 0.80 HTR6 (0.46) HTR6CCNE1CDK2HTR7
SCHEMBL3888391 0.80 HTR6 (0.65) HTR6CCNE1CDK2
SCHEMBL5726320 0.77 HTR6 (0.38) HTR6CCNE1CDK2
SCHEMBL7090612 0.77 HTR6 (0.41) HTR6CCNE1CDK2
SCHEMBL5725993 0.75 HTR6 (0.71) HTR6HTR1A
SCHEMBL5726115 0.73 HTR6 (0.69) HTR6
SCHEMBL1772003 0.72 BRD4 (0.55) HTR6HTR1ACCNE1CDK2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1355900-B1 HETEROCYCLYLALKYLINDOLE OR -AZAINDOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH CORP (US) 2006-05-24 — — EP claimed
US-20030225121-A1 Heterocyclylalkylindole or-azaindole compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2003-12-04 — — US claimed
US-20020128477-A1 Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands AMERICAN HOME PRODUCTS CORPORATION (US) 2002-09-12 — — US claimed
EP-1355900-B1 HETEROCYCLYLALKYLINDOLE OR -AZAINDOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH CORP (US) 2006-05-24 — — EP disclosed
US-20030225121-A1 Heterocyclylalkylindole or-azaindole compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2003-12-04 — — US disclosed
US-6613781-B2 Potential use in the treatment of a variety of central nervous system disorders such as anxiety, depression, epilepsy, obsessive-compulsive disorders, migraine, congnitive disorders, sleep disorders and schizophrenia WYETH 2003-09-02 — — US disclosed
US-20020128477-A1 Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands AMERICAN HOME PRODUCTS CORPORATION (US) 2002-09-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128477-A1 Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR1A HTR6 1/4885HTR1A 3/4885CCNE1 2435/4885
US-20030225121-A1 Heterocyclylalkylindole or-azaindole compounds as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR1A HTR6 1/4885HTR1A 3/4885CCNE1 2435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback